Title |
Synthesis of Ferromagnetic Fe0.6Mn0.4O Nanoflowers as a New Class of Magnetic Theranostic Platform for In Vivo T1‐T2 Dual‐Mode Magnetic Resonance Imaging and Magnetic Hyperthermia Therapy
|
---|---|
Published in |
Advanced Healthcare Materials, June 2016
|
DOI | 10.1002/adhm.201600357 |
Pubmed ID | |
Authors |
Xiao Li Liu, Cheng Teng Ng, Prashant Chandrasekharan, Hai Tao Yang, Ling Yun Zhao, Erwin Peng, Yun Bo Lv, Wen Xiao, Jie Fang, Jia Bao Yi, Huan Zhang, Kai-Hsiang Chuang, Boon Huat Bay, Jun Ding, Hai Ming Fan |
Abstract |
Uniform wüstite Fe0.6 Mn0.4 O nanoflowers have been successfully developed as an innovative theranostic agent with T1 -T2 dual-mode magnetic resonance imaging (MRI), for diagnostic applications and therapeutic interventions via magnetic hyperthermia. Unlike their antiferromagnetic bulk counterpart, the obtained Fe0.6 Mn0.4 O nanoflowers show unique room-temperature ferromagnetic behavior, probably due to the presence of an exchange coupling effect. Combined with the flower-like morphology, ferromagnetic Fe0.6 Mn0.4 O nanoflowers are demonstrated to possess dual-modal MRI sensitivity, with longitudinal relaxivity r1 and transverse relaxivity r2 as high as 4.9 and 61.2 mm(-1) s(-1) [Fe]+[Mn], respectively. Further in vivo MRI carried out on the mouse orthotopic glioma model revealed gliomas are clearly delineated in both T1 - and T2 -weighted MR images, after administration of the Fe0.6 Mn0.4 O nanoflowers. In addition, the Fe0.6 Mn0.4 O nanoflowers also exhibit excellent magnetic induction heating effects. Both in vitro and in vivo magnetic hyperthermia experimentation has demonstrated that magnetic hyperthermia by using the innovative Fe0.6 Mn0.4 O nanoflowers can induce MCF-7 breast cancer cell apoptosis and a complete tumor regression without appreciable side effects. The results have demonstrated that the innovative Fe0.6 Mn0.4 O nanoflowers can be a new magnetic theranostic platform for in vivo T1 -T2 dual-mode MRI and magnetic thermotherapy, thereby achieving a one-stop diagnosis cum effective therapeutic modality in cancer management. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
France | 1 | 2% |
Unknown | 64 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 11 | 17% |
Researcher | 10 | 15% |
Student > Master | 6 | 9% |
Unspecified | 5 | 8% |
Student > Doctoral Student | 3 | 5% |
Other | 10 | 15% |
Unknown | 20 | 31% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 7 | 11% |
Unspecified | 5 | 8% |
Chemistry | 5 | 8% |
Materials Science | 5 | 8% |
Physics and Astronomy | 5 | 8% |
Other | 14 | 22% |
Unknown | 24 | 37% |